Esophagogastroduodenoscopy
15
1
1
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
13.3%
2 terminated out of 15 trials
83.3%
-3.2% vs benchmark
20%
3 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (15)
Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding
Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper Endoscopy
Preoperative Viscous Lidocaine for Upper Gastrointestinal Endoscopy
Nausea and Vomiting Following Esophagogastroduodenoscopy: Prevalence and Predictive Factors
Efficacy and Safety of Etomidate Sedation in Gastric Endoscopic Submucosal Dissection
AQCS for Detection of Early Cancer and Precancerous Lesions on Upper Gastrointestinal Tract
Performance of a Single-use Gastroscope (aScope Gastro) for Esophagogastroduodenoscopy
Simulation-assisted Teaching in Learning Gastroscopy
Quality Control of Esophagogastroduodenoscopy Using Real-time EGD Auxiliary System
The Influence of Sedation for Endoscopy on Cognitive Function
NvisionVLE™ Registry System Registry
Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
Topical Pharyngeal Anesthesia in Sedated Esophagogastroduodenoscopy
Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol
Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy